2 results
Approved WMOCompleted
To demonstrate non-inferiority of a T2T strategy in which conventional synthetic disease modifying drugs (csDMARDs) refractory RApatients are initially treated with tsDMARD baricitinib versus the comparable T2T strategy in which patients are…
Approved WMORecruiting
To determine the dose-response relationship of VAY736 for key efficacy and safety parameters.